An evaluation of the societal costs and benefits of adjuvant trastuzumab in the treatment of early HER2neu-positive breast cancer in Singapore. Background: The era of cytostatic cancer agents requires ...
Patient-reported outcomes (PRO) in cancer trials submitted to the FDA from 2012-2015. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a full text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback